Page 72 - Read Online

Page 16 of 17 Rojas et al. Hepatoma Res 2018;4:31 I http://dx.doi.org/10.20517/2394-5079.2018.60

108. Jing W, Gao S, Zhu M, Luo P, Jing X, Chai H, Tu J. Potential diagnostic value of lncRNA SPRY4-IT1 in hepatocellular carcinoma. Oncol
Rep 2016;36:1085-92.
109. Li SP, Xu HX, Yu Y, He JD, Wang Z, Xu YJ, Wang CY, Zhang HM, Zhang RX, Zhang JJ, Yao Z, Shen ZY. LncRNA HULC enhances
epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1
signaling pathway. Oncotarget 2016;7:42431-46.
110. Xie H, Ma H, Zhou D. Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma. Biomed Res Int
2013;2013:136106.
111. Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S,
Ward SC, Bruix J, Mazzaferro V, Schwartz M, Friedman SL, Llovet JM. Wnt-pathway activation in two molecular classes of hepatocellular
carcinoma and experimental modulation by sorafenib. Clin Cancer Res 2012;18:4997-5007.
112. Ma X, Wang X, Yang C, Wang Z, Han B, Wu L, Zhuang L. DANCR acts as a diagnostic biomarker and promotes tumor growth and
metastasis in hepatocellular carcinoma. Anticancer Res 2016;36:6389-98.
113. El-Tawdi AHF, Matboli M, El-Nakeep S, Azazy AEM, Abdel-Rahman O. Association of long noncoding RNA and c-JUN expression in
hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2016;10:869-77.
114. Kamel MM, Matboli M, Sallam M, Montasser IF, Saad AS, El-Tawdi AHF. Investigation of long noncoding RNAs expression profile as
potential serum biomarkers in patients with hepatocellular carcinoma. Transl Res 2016;168:134-45.
115. Klingenberg M, Matsuda A, Diederichs S, Patel T. Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic
targets. J Hepatol 2017;67:603-18.
116. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with
suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009;28:3526-36.
117. Luo J, Chen M, Huang H, Yuan T, Zhang M, Zhang K, Deng S. Circulating microRNA-122a as a diagnostic marker for hepatocellular
carcinoma. Onco Targets Ther 2013;6:577-83.
118. Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, Huang L, Li H, Tan W, Wang C, Lin D. Circulating MicroRNAs, miR-21, miR-122, and miR-
223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011;50:136-42.
119. Kojima K, Takata A, Vadnais C, Otsuka M, Yoshikawa T, Akanuma M, Kondo Y, Kang YJ, Kishikawa T, Kato N, Xie Z, Zhang WJ,
Yoshida H, Omata M, Nepveu A, Koike K. MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness
of hepatocellular carcinoma. Nat Commun 2011;2:338.
120. Tan Y, Ge G, Pan T, Wen D, Chen L, Yu X, Zhou X, Gan J. A serum microrna panel as potential biomarkers for hepatocellular carcinoma
related with hepatitis b virus. PLoS One 2014;9:e66577.
121. Ali HEA, Abdel Hameed R, Effat H, Ahmed EK, Atef AA, Sharawi SK, Ali M, Abd Elmageed ZY, Abdel Wahab AH. Circulating
microRNAs panel as a diagnostic tool for discrimination of HCV-associated hepatocellular carcinoma. Clin Res Hepatol Gastroenterol
2017;41:e51-62.
122. Zekri ARN, Youssef ASED, El-Desouky ED, Ahmed OS, Lotfy MM, Nassar AAM, Bahnassey AA. Serum microRNA panels as potential
biomarkers for early detection of hepatocellular carcinoma on top of HCV infection. Tumor Biol 2016;37:12273-86.
123. El-Tawdi AHF, Matboli M, Shehata HH, Tash F, El-Khazragy N, Azazy AESM, Abdel-Rahman O. Evaluation of circulatory RNA-based
biomarker panel in hepatocellular carcinoma. Mol Diagnosis Ther 2016;20:265-77.
124. Okajima W, Komatsu S, Ichikawa D, Miyamae M, Kawaguchi T, Hirajima S, Ohashi T, Imamura T, Kiuchi J, Arita T, Konishi H, Shiozaki
A, Moriumura R, Ikoma H, Okamoto K, Taniguchi H, Itoh Y, Otsuji E. Circulating microRNA profiles in plasma: identification of miR-224
as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function. Oncotarget 2016;7:53820-36.
125. Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, Marubashi S, Tanemura M, Tomokuni A, Takemasa I, Umeshita K, Kanto T,
Doki Y, Mori M. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 2012;56:167-75.
126. Huang JT, Liu SM, Ma H, Yang Y, Zhang X, Sun H, Zhang X, Xu J, Wang J. Systematic review and meta-analysis: circulating miRNAs for
diagnosis of hepatocellular carcinoma. J Cell Physiol 2016;231:328-35.
127. Zhou L, Yang ZX, Song WJ, Li QJ, Yang F, Wang DS, Zhang N, Dou KF. MicroRNA-21 regulates the migration and invasion of a stem-like
population in hepatocellular carcinoma. Int J Oncol 2013;43:661-9.
128. Wang J, Li J, Shen J, Wang C, Yang L, Zhang X. MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of
hepatocellular carcinoma. BMC Cancer 2012;12:227.
129. Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis.
Cancer Cell 2016;30:836-48.
130. Jia S, Zocco D, Samuels ML, Chou MF, Chammas R, Skog J, Zarovni N, Momen-Heravi F, Kuo WP. Emerging technologies in extracellular
vesicle-based molecular diagnostics. Expert Rev Mol Diagn 2014;14:307-21.
131. Wendler F, Favicchio R, Simon T, Alifrangis C, Stebbing J, Giamas G. Extracellular vesicles swarm the cancer microenvironment: from
tumor-stroma communication to drug intervention. Oncogene 2017;36:877-84.
132. Witwer KW, Buzás EI, Bemis LT, Bora A, Lässer C, Lötvall J, Nolte-’t Hoen EN, Piper MG, Sivaraman S, Skog J, Théry C, Wauben MH,
Hochberg F. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles
2013;2:20360.
133. Conde-Vancells J, Rodriguez-Suarez E, Embade N, Gil D, Matthiesen R, Valle M, Elortza F, Lu SC, Mato JM, Falcon-Perez JM.
Characterization and comprehensive proteome profiling of exosomes secreted by hepatocytes. J Proteome Res 2008;7:5157-66.
134. Willms A, Müller C, Julich H, Klein N, Schwab R, Güsgen C, Richardsen I, Schaaf S, Krawczyk M, Krawczyk M, Lammert F, Schuppan D,
Lukacs-Kornek V, Kornek M. Tumour-associated circulating microparticles: a novel liquid biopsy tool for screening and therapy monitoring
of colorectal carcinoma and other epithelial neoplasia. Oncotarget 2016;7:30867-75.
135. Abbate V, Marcantoni M, Giuliante F, Vecchio FM, Gatto I, Mele C, Saviano A, Arciuolo D, Gaetani E, Ferrari MC, Giarretta I, Ardito F,
Riccardi L, Nicoletti A, Ponziani FR, Gasbarrini A, Pompili M, Pola R. HepPar1-positive circulating microparticles are increased in subjects
with hepatocellular carcinoma and predict early recurrence after liver resection. Int J Mol Sci 2017;18:E1043.